Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more

A focus on first-in-class innovation and solid tumor applications

Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential

BioCentury’s analysis of 25 first-in-human studies presented at AACR 2023

Ex-Roche exec refines focus, decides what to keep and commercialize vs. what to partner out

CAR T data at ASH could trigger more development in one of oncology’s less crowded cytokine spaces 

Presentations highlight gene edits and CAR engineering to improve efficacy of NK cell therapies

How Legend and Janssen gained the first FDA approval of a Chinese CAR T and what’s next for Legend’s pipeline

The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing 

Emerging Company Profile: With its R&D center up and running and a manufacturing facility by year-end, Cytovia aims to enter the clinic early 2022